
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Leyla Shune MD, discusses Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program.






